| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | ropinirole (Adartrel®) |
| Formulation | 0.25 mg, 0.5 mg and 2.0 mg film-coated tablet |
| Reference number | 265 |
| Indication | Symptomatic treatment of moderate to severe idiopathic restless legs syndrome |
| Company | GlaxoSmithKline |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 04/05/2006 |